New NIAID Radiation and Nuclear Countermeasures Program’s DAIT Council-Approved Research Concepts (January 27, 2014)
BAA-13-100-SOL-00013: Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures for BARDA. Posted July 31, 2013
BAA-13-100-SOL-00014: Science and Technology Platforms Applied to Medical Countermeasure Development (Innovations) for BARDA. Posted July 31, 2013
Contracts | Grants
2010 CMCR Individual Project Descriptions (PDF)
2005 CMCR Individual Project Descriptions (PDF)
Co-funded between the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the NIAID, the mission of this consortium of U01 awards is to "…advance the understanding of intestinal epithelial stem cell biology during development, homeostasis, regeneration and disease. The immediate goals of the ISCC are to isolate, characterize, culture and validate populations of intestinal stem cells; answer major questions in stem cell biology of the intestinal epithelium; and accelerate research by making information and resources available to the research community. Long-term goals include: 1) laying the ground work for therapeutic manipulation of the intestinal epithelium 2) contributing to the greater understanding of stem cell biology through knowledge of the intestine as a model stem cell-driven system."
Established in 2005, the Inter-Agency Agreement between the NIAID and the Armed Forces Radiobiology Research Institute (AFRRI) funds research in several areas related to the challenges encountered following radiological or nuclear events. These include: 1) Screen countermeasures to prevent, mitigate/ treat radiation injuries; 2) Automation of dicentric assay; 3) Develop animal model, study mechanism and screen countermeasures to mitigate/treat radiation combined injury; 4) Develop animal model, study mechanism and screen countermeasures to mitigate/treat gamma/neutron mixed field injury; 5) Develop Gottingen Minipig as a Model for Acute Radiation Syndrome.
NIAID-funded AFRRI’s screening program has performed toxicity studies, dose optimization, time optimization for post exposure, optimum route of administration and efficacy of post exposure (24 hr and beyond) administration of 55 single drugs and 3 combinations on survival in CD2F1 male mice at LD90/30 and LD70/30 doses. One of the promising drugs is being evaluated for post- exposure efficacy in non-human primate model. NIAID-funded work at AFFRI has automated dicentric sample processing and scoring with a throughput of approximately 1000 samples per day. In addition, AFRRI has developed and characterized rodent model for radiation+wound and radiation+burn combined injury as well as neutron (65%) + gamma (35%) mixed field injury, and efficacy evaluation of several potential countermeasures in these animal models is on-going. Also, AFRRI has developed and characterized Gottingen Minipig as a model for acute radiation syndrome.
The National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute (NCI) are cooperating on specific research ranging from identification, characterization and validation of safe and effective radiation/nuclear medical countermeasures, development of biology-based diagnostic assays or biomarkers to assess cellular and tissue damage following exposure to ionizing radiation and addressing other scientific areas with strong programmatic relevance, such as radiation epidemiology and radionuclide decorporation.
The following principal investigators within intramural NCI have projects being funded by this intramural opportunity within the NIAID Radiation/Nuclear Countermeasures Program:
Scientific accomplishments for this program include:
The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute on Aging (NIA) are cooperating on specific research and development projects to benefit both Institutes’ goals of advancing the study of immunesenescence from the natural process of aging and radiation exposure, and its amelioration in prevention and intervention therapies. Awarded in September, 2009, the following laboratories within intramural NIA are being funded:
These research projects, funded at the end of FY09, focus on how ionizing radiation and natural aging affect a person’s ability to respond to vaccination and the ability of the immune system to respond to vaccination and cause inflammation which is a hallmark of immune aging.
Last Updated December 20, 2012